LiMA Study for the treatment of methamphetamine dependence

A study of lisdexamfetamine for the treatment of methamphetamine dependence

Australia has one of the highest rates of methamphetamine dependence in the world. While counselling is effective for many people with less severe dependence, there is no proven medication treatment for severe dependence.

Lisdexamfetamine is a stimulant of the brain and is approved in Australia for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is a once-daily oral medication converted to dexamphetamine in the blood.

The aim of the LiMA study is to test if lisdexamfetamine is effective in reducing methamphetamine use, cravings and withdrawal symptoms. This will be a randomised double-blind placebo-controlled study which means that one group will receive lisdexamfetamine and another will receive a placebo (a medication with no active ingredients), in addition to counselling. Participants, clinicians and researchers involved in the study will not know to which group they have been allocated. The two groups will be compared and the findings will contribute to evidence for the future use of lisdexamfetamine in the treatment of methamphetamine dependence.

For further information regarding the LiMA study please contact Teodora Zanesheva on (02) 8382 4982 or email teodora.zanesheva@svha.org.au

 

This research project has been approved by St Vincent’s Hospital, Sydney Human Research Ethics Committee; reference number HREC/16/SVH/222.